1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2017-2028)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Region
2.2.1 Non-Insulin Therapies for Diabetes Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Size by Region (2017-2022)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2023-2028)
2.3 Non-Insulin Therapies for Diabetes Market Dynamics
2.3.1 Non-Insulin Therapies for Diabetes Industry Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2017-2022)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2017-2022)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2021
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2017-2022)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2023-2028)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2017-2022)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2017-2028)
6.2 North America Non-Insulin Therapies for Diabetes Market Size by Type
6.2.1 North America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
6.2.2 North America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
6.2.3 North America Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Application
6.3.1 North America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
6.3.2 North America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
6.3.3 North America Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country
6.4.1 North America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
6.4.2 North America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2017-2028)
7.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type
7.2.1 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
7.2.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
7.2.3 Europe Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application
7.3.1 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
7.3.2 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
7.3.3 Europe Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country
7.4.1 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
7.4.2 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2017-2028)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type
8.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application
8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region
8.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2017-2028)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type
9.2.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
9.2.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
9.2.3 Latin America Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application
9.3.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
9.3.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
9.3.3 Latin America Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country
9.4.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
9.4.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2017-2028)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type
10.2.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application
10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country
10.4.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.1.5 GSK Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.2.5 Eli Lilly Recent Developments
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.3.5 Sumitomo Dainippon Pharma Recent Developments
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Details
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.4.5 Intarcia Therapeutics Recent Developments
11.5 Servier
11.5.1 Servier Company Details
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.5.5 Servier Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.7.5 Merck Recent Developments
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Details
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.8.5 Dong-A Pharmaceutical Recent Developments
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Details
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.9.5 Luye Pharma Group Recent Developments
11.10 Eurofarma
11.10.1 Eurofarma Company Details
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.10.5 Eurofarma Recent Developments
11.11 Geropharm
11.11.1 Geropharm Company Details
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.11.5 Geropharm Recent Developments
11.12 Alkem Labs
11.12.1 Alkem Labs Company Details
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.12.5 Alkem Labs Recent Developments
11.13 SatRx
11.13.1 SatRx Company Details
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.13.5 SatRx Recent Developments
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Details
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Developments
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.15.5 Novo Nordisk Recent Developments
11.16 Emisphere
11.16.1 Emisphere Company Details
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.16.5 Emisphere Recent Developments
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Details
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.17.5 Uni-Bio Science Group Recent Developments
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.18.5 Takeda Recent Developments
11.19 3SBio
11.19.1 3SBio Company Details
11.19.2 3SBio Business Overview
11.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
11.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.19.5 3SBio Recent Developments
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Details
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.20.5 Jiangsu Hengrui Medicine Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
